1、Chen S, Wu J, Liang Y, Tang Y, Song H… Lu X, Chen SJ, Lu M, Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site, Cancer Cell, 2021, 39(2): 225-239

2、Tang Y, Song H, Wang Z, Xiao S… Liu F, Wu Y, Lu M, Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations, Cell Rep, 2022, 39(2):110622

3、Wang Z, Zhao Y, Wang Q, Xing Y, Feng L, Kong J… Zhang L, Yang H, Lu M, Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 Mpro, Signal Transduct Target Ther, 2021, 6(1):214

4、Yan N, Li Y, Xing Y, Wu J, Li J… Lu M, Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation, EMBO Rep, 2022, e54147

5、Wu J, Li Y, Wu J, Song H, Tang Y… Zhang S, Lu M, Decitabine activates type I interferon signaling to inhibit p53-deficient myeloid malignant cells, Clin Transl Med, 2021, (11):e593

1、Lu M, Zak J… Lu X, A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway, Cell, 2014, 157(5):1130-45

2、Lu M, Breyssens Hilde… Lu X, Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP, Cancer Cell, 2013, 23(5): 618-633

3、Lu M, Muers MR, Lu X, Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding, Nat Rev Mol Cell Biol, 2016, (8):523-32

4、Qin Y, Dai W, Wang Y, Gong XG, Lu M, Fe-SOD cooperates with Nutlin3 to selectively inhibit cancer cells in vitro and in vivo, Biochem Biophys Res Commun, 2013, 431(2):169-75

5、Lu M, Gong X, Lu Y, Guo J, Wang C, Pan Y, Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway, J Biol Chem, 2006, 281(19):13620-13627

1、Lu, Min; Wu, Jiale; Song, Huaxin. PANDA as a novel therapeutic, PCT/CN2018/085190。该专利进入中国2020071600684380；进入美国16959906；进入欧盟（28国）EP18898022.1；进入日本3148-PCT-JP；进入澳大利亚2018399726；进入加拿大0146523-00002。该专利部分国家地区使用权完成许可转化。该专利获第六届全国临床创新与发明大赛总决赛一等奖

2、Lu, Min; Wu, Jiale; Song, Huaxin. mp53 rescue compounds and methods of treating a p53 disorder, PCT/CN2019/070117。该专利进入中国2020071600808010；进入美国16959894；进入欧盟（28国）EP19736093.6；进入日本3147-PCT-JP；进入澳大利亚2019205062；进入加拿大0146523-00001

3、卢敏，梁颖，肖淑君，宋花歆；多功能p53复活药物及其用途，202110659536.4

4、卢敏，宋花歆；一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法，202110659578.8

5、Lu, Xin; Lu, Min. iASPP phosphorylation and metastatic potential. WIPO, WO 2013/131019 A1

1、临床试验Arsenic Trioxide in Refractory Solid Tumors with Rescuable p53 Mutation (https://www.clinicaltrials.gov/ct2/show/NCT04869475)

2、临床试验Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (https://www.clinicaltrials.gov/ct2/show/NCT03855371)

3、临床试验Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations (https://www.clinicaltrials.gov/ct2/show/NCT04906031)

4、TP53 Trust介绍（http://tp53.co.uk/interview-with-min-lu/）

5、AntiCancer Fund介绍（https://www.anticancerfund.org/en/blog/latest-news-about-drug-repurposing-oncology-4）